Abstract | OBJECTIVE: METHODS: RESULTS: Neoadjuvant combination therapy before radical prostatectomy decreased cancer- positive surgical margins from 33.8% in the control group to only 7.8%, thus leaving 92.2% of patients with negative margins at surgery. A net 54% improvement of staging was observed in favor of combination therapy. Organ-confined disease, on the other hand, increased from 49.3% to 77.8% of patients after 3 months of combination therapy, for a 57.8% increase in the incidence of organ-confined disease. No cancer was found in 6 (6.7%) prostatectomy specimens from the treated group. A close correlation was found between serum PSA at diagnosis and the stage of the disease at surgery. Upstaging increased from 30% at serum PSA values of 0 to 3.0 ng/mL up to 100% at serum PSA values above 15 ng/mL. CONCLUSIONS: Although long-term follow-up of these patients is required to determine the impact on survival, the marked influence of neoadjuvant combination therapy on the stage of the disease suggests the possibility of a major improvement in the morbidity and mortality from prostate cancer.
|
Authors | F Labrie, L Cusan, J L Gomez, P Diamond, R Suburu, M Lemay, B Tetu, Y Fradet, A Bélanger, B Candas |
Journal | Urology
(Urology)
Vol. 49
Issue 3A Suppl
Pg. 56-64
(Mar 1997)
ISSN: 0090-4295 [Print] United States |
PMID | 9123738
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Androgen Antagonists
- Gonadotropin-Releasing Hormone
- Flutamide
- Prostate-Specific Antigen
|
Topics |
- Adenocarcinoma
(blood, drug therapy, pathology, surgery)
- Aged
- Androgen Antagonists
(therapeutic use)
- Canada
- Chemotherapy, Adjuvant
- Drug Therapy, Combination
- Flutamide
(therapeutic use)
- Follow-Up Studies
- Gonadotropin-Releasing Hormone
(agonists)
- Humans
- Male
- Middle Aged
- Neoplasm Staging
- Prospective Studies
- Prostate-Specific Antigen
(blood)
- Prostatic Neoplasms
(blood, drug therapy, pathology, surgery)
|